Royalty Report: Drugs, Kidneys, Diagnostic – Collection: 330753


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Kidneys
  • Diagnostic
  • Cancer
  • cardiac
  • Molecular
  • Drug Discovery
  • Autoimmune
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 330753

License Grant
Licensor grants global rights, excluding Greater China, to develop, manufacture and commercialize ANG-3777.

Under the License, Licensor is responsible for executing a pre-specified clinical development plan designed to obtain regulatory approvals of ANG-3777 for DGF and CSA-AKI.

Licensee holds global exclusive rights to commercialize ANG-3777 for this indication, except in Greater China, where licensed development and commercialization rights are granted exclusively to another party.

License Property
Licensor is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.

Licensor has ANG-3777 technology relating to acute organ injury, effective organ self-repair hindered by a naturally-occurring mismatch in timing of peak levels of HGF concentration relative to c-Met expression, an issue that could be addressed by augmenting the activity of HGF with our HGF mimetic during the time of maximal c-Met expression. ANG-3777 has demonstrated several similarities to HGF, including c-Met dependence and selective c-Met receptor activation, without acting on other growth factor receptors.

ANG-3777, an HGF Mimetic, is a small molecule designed to mimic the biological activity of HGF. HGF activates the c-Met receptor, which triggers a cascade of pathways with a central role in tissue repair and organ recovery that has been well established.

Field of Use
The field of use is all therapeutic, prophylactic and diagnostic uses for renal indications, including forms of AKI, acute kidney injury, and congestive heart failure (collectively, the Renal Indications).

ANG-3777 for CSA-AKI means for patients at risk for developing CSA-AKI. This indication is a frequent complication of cardiac surgery.

ANG-3777 for DGF means to improve kidney function and reduce the severity of DGF following deceased-donor kidney transplantation in patients showing evidence of early kidney dysfunction.

IPSCIO Record ID: 352555

License Grant
Licensee acquired an exclusive royalty-bearing worldwide license from Licensor of Singapore to develop, make, have made, use, practice, research, distribute, lease, sell, offer for sale, license, import or otherwise dispose of certain rights owned or controlled by Licensor and/or any of its affiliates, related to UNI 494 and a non-exclusive license to certain know-how and technology related to the UNI 494 Rights.
License Property
UNI 494 (a patented prodrug of nicorandil) has the potential to be a first-in-class drug for the treatment of acute kidney injury (AKI).

UNI 494 is a patented pro-drug that was designed to be absorbed into the systemic circulation, and once absorbed, to release nicorandil into the bloodstream. By avoiding direct exposure to the gastrointestinal tract of nicorandil, it is believed that UNI 494 may be able to minimize or avoid the gastrointestinal side effects of nicorandil. Also, based on the rate of conversion of UNI 494 to nicorandil in the systemic circulation, UNI 494 may offer greater and/or more prolonged exposure to nicorandil for the treatment of patients with acute kidney injury.

Nicorandil, marketed in such products as Ikorel and Dancor, is indicated for the treatment of chronic stable angina pectoris. Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic guanosine monophosphate (GMP). It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload.

Field of Use
Field of use is for treatment of acute kidney injury (AKI).

AKI is a sudden episode of kidney failure or kidney damage (within the first 90 days of injury). After 90 days, the patient is considered to have progressed into CKD. Chronic kidney disease (CKD) is the gradual loss of kidney function that can get worse over time leading to lasting damage.

IPSCIO Record ID: 304790

License Grant
Licensee of Sweden was granted (i) an exclusive license to certain patents and joint intellectual property developed with Licensor and (ii) a non-exclusive license to certain of Licensor know-how as necessary or useful to develop and commercialize Nefecon or other product candidates.
License Property
Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant. Nefecon is currently the only pharmaceutical candidate in development for IgAN that is intended to be disease-modifying. Nefecon targets the ileum, the distal region of the small intestine, which is the presumed origin of IgAN due to the ileum being the location of the highest concentration of the Peyer’s patches, which are responsible for the production of secretory immunoglobulin A, or IgA, antibodies. Nefecon has been granted orphan drug designation for the treatment of IgAN in the United States and the European Union.
Field of Use
The filed of use is for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN for which there is a high unmet medical need and there are no approved treatments. IgAN is a progressive, chronic disease that over time results in deterioration of kidney function in patients, many of whom end up at risk of developing end-stage renal disease, or ESRD, with the need for dialysis or kidney transplant.

IgA nephropathy (IgAN), also known as Berger's disease or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of the disease) can attack other major organs, such as the liver, skin and heart.

Licensee is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.  Licensee expects that Nefecon will be the first treatment on the market indicated for IgAN, and, that Nefecon can successfully treat IgAN patients, their kidney function will be preserved.

IPSCIO Record ID: 284140

License Grant
Licensor granted Licensee worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.
License Property
Capmatinib is a potent and highly selective MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure MET signaling and MET dependent cell proliferation, survival and migration.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.
Field of Use
Capmatinib is being evaluated in patients with hepatocellular carcinoma, non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.

IPSCIO Record ID: 35129

License Grant
Licensor of Hong Kong grants to Licensee of Sweden, a co-exclusive license, with the right to sublicense  under the Licensor Technology and Licensor's interest in the Joint Technology, to Develop the Collaboration Compound and Collaboration Products in the Field in the Territory in accordance with the terms of this Agreement and an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensor Technology and Licensor's interest in the Joint Technology, to Manufacture and Commercialize the Collaboration Products in the Field in the Territory.

For Licensee's Right of Reference. Licensor grants to Licensee and its Sublicensees a Right of Reference to all data included in the Regulatory Submissions and Regulatory Approvals Controlled by Licensor and its Affiliates relating to a Collaboration Compound or Collaboration Products to the extent necessary to obtain Regulatory Approval of any Collaboration Product in the Field in any country of the ROW Territory.

Each Party grants the other Party a worldwide, irrevocable, non-exclusive, perpetual, freely sublicensable right and license to exploit the Joint Technology in any manner without compensation.

License Property
Licensor owns or otherwise controls certain patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to the research, development and manufacture of the c-Met inhibitor known as HMPL-504.

The Agreement Compound means any compound with a molecular weight less than 1000 Da, other than a Collaboration Compound, that specifically targets the Collaboration Target and lacks material activity against other pharmaceutical targets (i.e. the IC50 value of such compound or product against another pharmaceutical target is more than thirty (30) times greater than the IC50 value of such compound or product against the Collaboration Target).

The Collaboration Compound means Licensor's proprietary compound designated by Licensor on the Effective Date as HMPL-504, with the generic name Volitinib, a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Volitinib, which will imminently enter Phase I testing, has been discovered and developed in China.  Volitinib is a potent and highly selective c-Met inhibitor, which has been demonstrated to inhibit the growth of tumors in a series of pre-clinical disease models, especially for those tumors with aberrant c-Met signalling such as gene amplification or c-Met over-expression.

The key patent is Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor.

Savolitinib is a potential global first-in-class inhibitor of the mesenchymal epithelial transition factor, or c-Met, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors. We developed savolitinib as a potent and highly selective oral inhibitor that was designed to address renal toxicity, the primary issue that has prevented all other selective c-Met inhibitors from gaining regulatory approval. In Phase I clinical studies, savolitinib has shown promising signs of clinical efficacy, causing tumor size reduction in patients with c-Met gene amplification in papillary renal cell carcinoma, non-small cell lung cancer, colorectal cancer and gastric cancer.

Field of Use
This agreement pertains to drugs for all diagnostic, prophylactic and therapeutic uses in the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.